In the dose sub-group, PPAR-γ agonist therapy may have dose-dependent effects, where increasing the dosage of the PPAR-γ agonist may lead to lower ADAS-Cog clinical scores (L/Low dose/2 mg: SMD = −0.08, 95% CI [−0.16, 0.00], I2 = 0%; H/High dose/15 mg: SMD = −0.39, 95% CI [−0.70, −0.08], I2 = 28.6%), meaning AD patients using a higher dose of PPAR-γ agonist therapy may have a better therapeutic outcome. Here, PPARG is linked to Alzheimer disease.